Nkarta, Inc. Common Stock (NKTX) Stock Price
NKTXStock
$2.76+25.45%52W
Market Cap$197.68M
P/E—
PEG Ratio—
Div yield—
Beta0.94
NKTX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-1.97%
Price vs S&P 500 (4W)26.83%
VGM Score57.59
NKTX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.36 | -$0.54 | -48.63%(-$0.18) | |
| Q4 2025 | -$0.29 | -$0.37 | -25.42%(-$0.08) | |
| Q3 2025 | -$0.31 | -$0.29 | +7.45%(+$0.02) | |
| Q2 2025 | -$0.35 | -$0.31 | +11.43%(+$0.04) |
NKTX Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.27
4.30
4.25
4.25
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NKTXNkarta, Inc. Common Stock | — | — | C | $2.76 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Nkarta, Inc. Common Stock
Nkarta is a clinical-stage biopharmaceutical company developing off-the-shelf allogeneic natural killer (NK) cell therapies for cancer treatment. The company combines proprietary NK cell expansion technology with engineered cell recognition capabilities to enhance therapeutic targeting and persistence. This approach aims to generate an abundant supply of engineered NK cells that can identify and eliminate cancer cells while triggering durable immune responses.